Oral administration of 3,3′-diindolylmethane inhibits lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice

Journal of Nutrition

Volumn 139, Issue 12, 2009, Pages 2373-2379

  Kim, Eun Ji ^a   Shin, Minjeong ^a   Park, Heesook ^a   Hong, Ji Eun ^a   Shin, Hyun Kyung ^a   Kim, Jongdai ^b   Kwon, Dae Young ^c   Park, Jung Han Yoon ^a  

^a Hallym University   (South Korea)

^b Kangwon National University   (South Korea)

^c Korea Food Research Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG; LUNG METASTASIS; LUNG NODULE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; SERUM; TREATMENT DURATION;

ANIMALS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; INTERCELLULAR ADHESION MOLECULE-1; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR CELL ADHESION MOLECULE-1;

MURINAE; MUS;

EID: 72249116503     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.109.111864     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Ali SM, Harvey HA, Lipton A. Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res. 2003;S132-7.
3. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591-602.
4. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995;55:1856-1862
5. Orhan B. Doxorubicin cardiotoxicity: growing importance. J Clin Oncol. 1999;17:2294-2296
6. De Kruif CA, Marsman JW, Venekamp JC, Falke HE, Noordhoek J, Blaauboer BJ, Wortelboer HM. Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chem Biol Interact. 1991;80:303-315
7. Chen I, McDougal A, Wang F, Safe S. Aryl hydrocarbon receptormediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis. 1998;19:1631-1639
8. Wattenberg LW, Loub WD. Inhibition of polycyclic aromatic hydrocarbon- induced neoplasia by naturally occurring indoles. Cancer Res. 1978;38:1410-1413
9. Chang X, Tou JC, Hong C, Kim HA, Riby JE, Firestone GL, Bjeldanes LF. 3,39-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis. 2005;26:771-778
10. Kim EJ, Park SY, Shin HK, Kwon DY, Surh YJ, Park JH. Activation of caspase-8 contributes to 3,3′-Diindolylmethane-induced apoptosis in colon cancer cells. J Nutr. 2007;137:31-36
11. Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S. 3,3′- diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis. 2006;27:717-728
12. Garikapaty VP, Ashok BT, Tadi K, Mittelman A, Tiwari RK. 3,3′- Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun. 2006;340:718-725
13. Wang Z, Yu BW, Rahman KM, Ahmad F, Sarkar FH. Induction of growth arrest and apoptosis in human breast cancer cells by 3,3- diindolylmethane is associated with induction and nuclear localization of p27kip. Mol Cancer Ther. 2008;7:341-349
14. Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S, Sarkar FH. Inactivation of uPA and its receptor uPAR by 3,3′-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem. 2009.
15. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,39-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007;67:3310-3319
16. Kim EJ, Holthuizen PE, Park HS, Ha YL, Jung KC, Park JH. Trans-10, cis-12-conjugated linoleic acid inhibits Caco-2 colon cancer cell growth. Am J Physiol Gastrointest Liver Physiol. 2002;283:G357-67.
17. Kim EJ, Lee YJ, Shin HK, Park JH. Induction of apoptosis by the aqueous extract of Rubus coreanum in HT-29 human colon cancer cells. Nutrition. 2005;21:1141-1148
18. Lim DY, Tyner AL, Park JB, Lee JY, Choi YH, Park JH. Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1. J Cell Physiol. 2005;205:107-113
19. Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, Park JH. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem. 2009;20:663-676
20. Cho HJ, Kim WK, Kim EJ, Jung KC, Park S, Lee HS, Tyner AL, Park JH. Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am J Physiol Gastrointest Liver Physiol. 2003;284:G996-1005.
21. Cho HJ, Seon MR, Lee YM, Kim J, Kim JK, Kim SG, Park JH. 3,3′- Diindolylmethane suppresses the inflammatory response to lipopolysaccharide in murine macrophages. J Nutr. 2008;138:17-23.
22. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52:1399-1405
23. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer. 1999;81:1311-1317
24. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D, Dong Z. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer. 2002;101:415-422
25. Ebert O, Harbaran S, Shinozaki K, Woo SL. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 2005;12:350-358
26. Coffey JC, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP. The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy. Ann Surg. 2006;243:250-256
27. Hu J, Verkman AS. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J. 2006;20:1892-1894
28. Nachshon-Kedmi M, Fares FA, Yannai S. Therapeutic activity of 3,3′- diindolylmethane on prostate cancer in an in vivo model. Prostate. 2004;61:153-160
29. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996;3:895-904.
30. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252-257
31. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD. Circulating MMP2 and MMP9 in breast cancer- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer. 2006;119: 1403-1411
32. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6:227-239
33. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267-283
34. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol. 1995;7:728-735
35. Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, Park JH. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. The Journal of nutritional biochemistry. 2008.
36. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25:99-113.
37. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122
38. Kuvaja P, Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma. Int J Cancer. 2008;123:846-851
39. Kumar AG, Dai XY, Kozak CA, Mims MP, Gotto AM, Ballantyne CM. Murine VCAM-1. Molecular cloning, mapping, and analysis of a truncated form. J Immunol. 1994;153:4088-4098
40. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068-2101
41. Coskun U, Sancak B, Sen I, Bukan N, Tufan MA, Gulbahar O, Sozen S. Serum P-selectin, soluble vascular cell adhesion molecule-I (s-VCAM-I) and soluble intercellular adhesion molecule-I (s-ICAM-I) levels in bladder carcinoma patients with different stages. Int Immunopharmacol. 2006;6:672-677
42. Polychronidis AC, Tsaroucha AK, Samolis SP, Botaitis SK, Perente SS, Simopoulos CE. Serum levels of intercellular adhesion molecule- 1 correlate with advanced and metastatic disease and poor prognosis in gastric cancer. Folia Med (Plovdiv). 2003;45:20-24
43. Valdivia-Silva JE, Franco-Barraza J, Silva AL, Pont GD, Soldevila G, Meza I, Garcia-Zepeda EA. Effect of pro-inflammatory cytokine stimulation on human breast cancer: Implications of chemokine receptor expression in cancer metastasis. Cancer Lett. 2009.
44. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, et al. Expression of interleukin-1beta in human breast carcinoma. Cancer. 1997;80:421-434
45. Ahmed OI, Adel AM, Diab DR, Gobran NS. Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol. 2006;13:61-68
46. Parkos CA, Colgan SP, Diamond MS, Nusrat A, Liang TW, Springer TA, Madara JL. Expression and polarization of intercellular adhesion molecule-1 on human intestinal epithelia: consequences for CD11b/ CD18-mediated interactions with neutrophils. Mol Med. 1996; 2:489-505.
47. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135-141
48. Huang HC, Huang CY, Lin-Shiau SY, Lin JK. Ursolic acid inhibits IL- 1beta or TNF-alpha-induced C6 glioma invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression. Mol Carcinog. 2009;48:517-531
49. Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, Mager DE. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos. 2004;32: 632-638